Compare RNTX & JG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNTX | JG |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.5M | 40.6M |
| IPO Year | N/A | 2018 |
| Metric | RNTX | JG |
|---|---|---|
| Price | $1.15 | $7.40 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 201.0K | 7.1K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $50,967,244.00 |
| Revenue This Year | N/A | $10.90 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.78 |
| 52 Week Low | $1.02 | $5.75 |
| 52 Week High | $3.50 | $20.94 |
| Indicator | RNTX | JG |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 65.28 |
| Support Level | $1.09 | $6.84 |
| Resistance Level | $1.26 | $7.95 |
| Average True Range (ATR) | 0.09 | 0.38 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 44.73 | 79.61 |
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
Aurora Mobile Ltd provides stable, and accurate developer services for educational and medical products. It is focused on providing companies with stable and efficient push notification services. It provides a comprehensive suite of services to mobile app developers in mainland China. Through its developer services, it gains access to, aggregate, cleanse, structure and encrypt vast amounts of real-time and anonymous device-level mobile behavioral data. It offers data services such as iAPP which helps the investors to analyze opportunities in the sector, Anti-fraud helps to identify fraud risks, iAudience, iZone and other related services. The company operates and generates its revenue from the People's Republic of China.